Non-Small Cell Lung Cancer (NSCLC)

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.

Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

This video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.

This video segment explores the potential role of KRAS-targeted therapies in the frontline treatment of KRAS-positive metastatic NSCLC, highlighting considerations for specific patient populations and disease characteristics.

This video segment examines strategies for managing adverse events associated with adagrasib, comparing its safety profile to other RAS GTPase inhibitors like sotorasib, and discusses key differences, benefits, and risks that may influence treatment selection or consideration of clinical trials.

Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.

Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

This video segment discusses the efficacy and safety profile of adagrasib for KRAS-positive metastatic NSCLC, drawing insights from the KRYSTAL-1 trial data to inform treatment sequencing decisions.

A 58-year-old retired teacher treated with adagrasib for KRAS+ metastatic NSCLC.

Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.

Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

This video segment explores emerging investigational agents for the management of metastatic ALK-positive NSCLC, highlighting promising advancements in the treatment landscape.

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Christine Bestvina, MD, stated that the presence of EGFR and ALK mutations can affect the way that a patient will react to treatment and should be factors that physicians consider.

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.

“We need some longer-term overall survival data to help discuss with patients the best treatment of choice for them,” Christine Bestvina, MD, said.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.

This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.